Seattle Genetics’ cancer drug put on clinical hold after four deaths

(Reuters) – Seattle Genetics Inc said four people had died in trials testing its experimental cancer drug, prompting the U.S. Food and Drug Administration to impose a clinical hold on several early-stage studies. The company’s shares fell 14.6 percent to $52.85 in premarket trading. Six patients with acute myeloid leukemia (AML), a type of blood cancer, have been identified with liver toxicity and four have died, the company said on Tuesday.
Go to Source